4SC’s IBD drug Vidofludimus generates response rate of 88.5%
Planegg-Martinsried – Drug discovery specialist 4SC AG’s oral immunosuppressant Vidofludimus (SC12267, 4SC-101) has provided promisingdata in an exploratory open-label Phase IIa study on 34 patients with inflammatory bowel disease. After a once-daily dose of the oral IL17 and dihydroorate dehydrogenase inhibitor (35 mg) over 12 weeks 88.5% of corticosteroid-dependent IBD patients showed complete or partial response to the DMARD. This compares to an approximately 20% average placebo response across published benchmark clinical trials, 4SC announced. Disease remission was maintained in 14 out of 26 patients (53.9%) without intake of corticosteroids (complete responders), according to the preliminary results. A further 9 out of 26 patients (34.6%) remained in remission at the end of the study treatment period at a corticosteroid dose equal to or below the patients' individual threshold doses (partial responders). Additionally, Vidofludimus was well tolerated with no critical safetyissues observed. 4SC-101 is also being tested in a Phase IIb study in rheumatoid arthritis.